Reinhart Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Reinhart Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-120,981	Closed	-$1.46M	–	175
2015 Q1	$1.46M	Sell	120,981 -9,730	-7%	-$91.9K	0.11%	122
2014 Q4	$1.08M	Buy	130,711 +1,300	+1%	+$10.9K	0.08%	132
2014 Q3	$1.13M	Sell	129,411 -23,620	-15%	-$213K	0.08%	132
2014 Q2	$1.68M	Buy	153,031 +1,000	+0.7%	+$8.91K	0.12%	119
2014 Q1	$1.36M	Sell	152,031 -5,789	-4%	-$53.3K	0.1%	128
2013 Q4	$1.19M	Buy	157,820 +8,900	+6%	+$62.2K	0.09%	130
2013 Q3	$1.09M	Buy	+148,920	New	+$1M	0.09%	141

Other funds holding SUPN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MRM

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KIA

Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Reinhart Partners's SUPN Position: Q2 2015 in Review

Reinhart Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 120,981 shares — an estimated $1.46M sold.

Reinhart Partners first reported a position in SUPN in Q3 2013 and held it in 7 quarters. The position peaked at $1.68M in Q2 2014. 165 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

Reinhart Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Reinhart Partners sold 120,981 Supernus Pharmaceuticals shares in Q2 2015, an estimated $1.46M.
Reinhart Partners first reported a position in Supernus Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Reinhart Partners's Supernus Pharmaceuticals position peaked at $1.68M in Q2 2014.
165 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Reinhart Partners's 13F filing for Q2 2015, filed 7 Jul 2015.